← Leaderboards
Neil S Shachter
Columbia University Health Sciences
$3,783,300
Attributed
$3,783,300
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$3,783,300 · 3
By mechanism
R01$3,783,300 · 3
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Alan Richard Tall$42,229,886
- Henry N Ginsberg$119,772,603
- Ira A Tabas$44,847,082
- Richard Mayeux$113,943,785
- Davangere P Devanand$43,591,695
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseBlood Lipoprotein MetabolismGenetically Modified AnimalsTissue /Cell CultureDisease /Disorder ModelVery Low Density LipoproteinAtherosclerosisBody CompositionCooperative StudyDrug Adverse EffectHiv InfectionsHyperlipidemiaPharmacokineticsProtease InhibitorApolipoproteinsDiabetic AngiopathyHeparan SulfateProteoglycanBasement MembraneCholesterolMolecular PathologyDietary LipidDiabetes MellitusMucopolysaccharides
Grant awards (11)
Decreased Perlecan in Experimental Models of Diabetes$408,750
R01 · FY2005 · HL
Decreased Perlecan in Experimental Models of Diabetes$408,750
R01 · FY2004 · HL
BASIC MECHANISMS OF PROTEASE INHIBITOR DYSLIPIDEMIA$383,625
R01 · FY2004 · HL
Decreased Perlecan in Experimental Models of Diabetes$408,750
R01 · FY2003 · HL
BASIC MECHANISMS OF PROTEASE INHIBITOR DYSLIPIDEMIA$383,625
R01 · FY2003 · HL
Decreased Perlecan in Experimental Models of Diabetes$408,750
R01 · FY2002 · HL
BASIC MECHANISMS OF PROTEASE INHIBITOR DYSLIPIDEMIA$383,625
R01 · FY2002 · HL
BASIC MECHANISMS OF PROTEASE INHIBITOR DYSLIPIDEMIA$383,625
R01 · FY2001 · HL
NEW TRANSGENIC MODELS OF HYPERTRIGLYCERIDEMIA$107,415
R01 · FY2001 · HL
BASIC MECHANISMS OF PROTEASE INHIBITOR DYSLIPIDEMIA$383,625
R01 · FY2000 · HL
NEW TRANSGENIC MODELS OF HYPERTRIGLYCERIDEMIA$122,760
R01 · FY2000 · HL